Korean J Androl.  2011 Aug;29(2):161-167. 10.5534/kja.2011.29.2.161.

The Effect of 5-alpha Reductase Inhibitors on the Efficacy of Photoselective Vaporization of the Prostate with 120 W GreenLight HPS Laser

• Park HJ
• Kim HW
• Kim TN
• Park NC

• KMID: 2226470
• DOI: http://doi.org/10.5534/kja.2011.29.2.161

Abstract

PURPOSE
To evaluate the effect of preoperative 5-alpha reductase inhibitor (ARI) administration on the operative results of photoselective vaporization of prostate with 120W GreenLight HPS laser.
MATERIALS AND METHODS
Data were collected from 98 benign prostatic hyperplasia (BPH) patients who underwent transurethral electrovaporization of prostate by 120W Greenlight HPS laser between Jan. 2010 and Dec. 2010. We compared the time of operation, the energy required in lasering, postoperative maximum uroflow velocity, change in residual urine volume and complications between 5-ARI administrating group and control group.
RESULTS
56 patients administrated 5-ARI at least 3 months before surgery. 30 and 26 patients administrated finasteride and dutasteride, respectively. Mean follow up period was 4.1+/-1.8 months. Mean age of the subjects and mean prostate volume were not different. Mean change of postoperative hemoglobin, lasing time and energy required in lasering were greater in 5-ARI administrating group. There were 3 and 1 cases of acute urinary retension in 5-ARI administrating group and control group, respectively.
CONCLUSIONS
The mean change of hemoglobin and mean energy required in lasering were greater and mean lasing time was longer in the patients who administrated 5-ARI before photoselective vaporization of prostate by 120W Greenlight HPS laser. Further investigation and extensive study will be needed to confirm these results.

Keyword

Prostate hyperplasia; 5-alpha reductase inhibitors; Transurethral vaporesection of prostate

MeSH Terms

5-alpha Reductase Inhibitors
Azasteroids
Finasteride
Follow-Up Studies
Hemoglobins
Humans
Oxidoreductases
Prostate
Prostatic Hyperplasia
Transurethral Resection of Prostate
Volatilization
Dutasteride
5-alpha Reductase Inhibitors
Azasteroids
Finasteride
Hemoglobins
Oxidoreductases

Reference

1). Yu X, Elliott SP, Wilt TJ, McBean AM. Practice patterns in benign prostatic hyperplasia surgical therapy: the dramatic increase in minimally invasive technologies. J Urol. 2008; 180:241–5.

2). Kuntzman RS, Malek RS, Barrett DM. High-power potassium titanyl phosphate laser vaporization prostatectomy. Mayo Clin Proc. 1998; 73:798–801.

3). Choo SH, Han DH, Lee SW. The efficacy and safety of KTP photoselective vaporization of the prostate for the treatment of benign prostatic hyperplasia: the 2-year results. Korean J Urol. 2008; 49:831–6.

4). Malek RS, Kuntzman RS, Barrett DM. Photoselective potassium-titanyl-phosphate laser vaporization of the benign obstructive prostate: observations on longterm outcomes. J Urol. 2005; 174:1344–8.

5). Ko DW, Jeong BC, Son H. Initial experiences with a new 120 W greenlight(TM) high-power system for photoselective vaporization of the prostate for the treatment of benign prostatic hyperplasia in Korea. Korean J Urol. 2009; 50:1089–94.

6). Bepple JL, Barone BB, Eure G. The effect of dutasteride on the efficacy of photoselective vaporization of the prostate: results of a randomized, placebo-controlled, double-blind study (DOP trial). Urology. 2009; 74:1101–4.

7). Choi HR, Chung WS, Shim BS, Kwon SW, Hong SJ, Chung BH, et al. Translation validity and reliability of I-PSS Korean version. Korean J Urol. 1996; 37:659–65.

8). Stovsky MD, Rhee K, Hartke D. Medical therapy versus surgery and minimally invasive surgical therapies for lower urinary tract symptoms and benign prostatic hyperplasia: what makes better economic sense? Curr Urol Rep. 2007; 8:289–97.

9). Kaplan SA, Te AE. Transurethral electrovaporization of the prostate: a novel method for treating men with benign prostatic hyperplasia. Urology. 1995; 45:566–72.

10). Hwang EC, Joo JS, Min KD, Oh BR, Kang TW, Kwon DD, et al. A short-term comparative study on efficacy and safety of standard transurethral resection and high power (80W) potassium-titanyl-phosphate laser vaporization of the prostate. Korean J Urol. 2005; 46:1251–5.

11). Park JS, Min GE, You CH, Hong B, Kim CS, Ahn H, et al. Comparison of treatment outcomes between photoselective vaporization and transurethral resection of the prostate for benign prostatic hyperplasia. Korean J Urol. 2007; 48:297–303.

12). Te AE, Malloy TR, Stein BS, Ulchaker JC, Nseyo UO, Hai MA, et al. Photoselective vaporization of the prostate for the treatment of benign prostatic hyperplasia: 12-month results from the first United States multicenter prospective trial. J Urol. 2004; 172:1404–8.

13). Bachmann A, Schürch L, Ruszat R, Wyler SF, Seifert HH, Müller A, et al. Photoselective vaporization (PVP) versus transurethral resection of the prostate (TURP): a prospective bi-centre study of perioperative morbidity and early functional outcome. Eur Urol. 2005; 48:965–71.

14). Hwang EC, Joo JS, Min KD, Oh BR, Kang TW, Kwon DD, et al. A short-term comparative study on efficacy and safety of standard transurethral resection and high power (80W) potassium-titanyl-phosphate laser vaporization of the prostate. Korean J Urol. 2005; 46:1251–5.

15). Cha WH, Jang TJ, Lee KS. Expression of Survivin and Bcl-2 in Benign Prostatic Hyperplasia Treated with a 5-alpha-reductase Inhibitor. Korean J Urol. 2008; 49:242–7.

16). Huynh H, Seyam RM, Brock GB. Reduction of ventral prostate weight by finasteride is associated with suppression of insulin-like growth factor I (IGF-I) and IGF-I receptor genes and with an increase in IGF binding protein 3. Cancer Res. 1998; 58:215–8.

17). Clark RV, Hermann DJ, Cunningham GR, Wilson TH, Morrill BB, Hobbs S. Marked suppression of dihydrotestosterone in men with benign prostatic hyperplasia by dutasteride, a dual 5alpha-reductase inhibitor. J Clin Endocrinol Metab. 2004; 89:2179–84.

18). Marihart S, Harik M, Djavan B. Dutasteride: a review of current data on a novel dual inhibitor of 5alpha reductase. Rev Urol. 2005; 7:203–10.

19). Hochberg DA, Basillote JB, Armenakas NA, Vasovic L, Shevchuk M, Pareek G, et al. Decreased suburethral prostatic microvessel density in finasteride treated prostates: a possible mechanism for reduced bleeding in benign prostatic hyperplasia. J Urol. 2002; 167:1731–3.

20). Pareek G, Shevchuk M, Armenakas NA, Vasjovic L, Hochberg DA, Basillote JB, et al. The effect of finasteride on the expression of vascular endothelial growth factor and microvessel density: a possible mechanism for decreased prostatic bleeding in treated patients. J Urol. 2003; 169:20–3.

21). Puchner PJ, Miller MI. The effects of finasteride on hematuria associated with benign prostatic hyperplasia: a preliminary report. J Urol. 1995; 154:1779–82.

22). Hagerty JA, Ginsberg PC, Harmon JD, Harkaway RC. Pretreatment with finasteride decreases perioperative bleeding associated with transurethral resection of the prostate. Urology. 2000; 55:684–9.

23). Canda AE, Mungan MU, Yilmaz O, Yorukoglu K, Tuzel E, Kirkali Z. Effects of finasteride on the vascular surface density, number of microvessels and vascular endothelial growth factor expression of the rat prostate. Int Urol Nephrol. 2006; 38:275–80.